Wall Street brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to announce earnings per share (EPS) of ($1.18) for the current quarter, Zacks reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.25) and the highest estimate coming in at ($1.06). Theravance Biopharma posted earnings of ($1.22) per share during the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The firm is expected to announce its next quarterly earnings results on Tuesday, May 14th.
On average, analysts expect that Theravance Biopharma will report full year earnings of ($4.66) per share for the current financial year, with EPS estimates ranging from ($5.20) to ($3.47). For the next year, analysts forecast that the company will post earnings of ($4.63) per share, with EPS estimates ranging from ($6.10) to ($3.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Theravance Biopharma.
A number of research analysts have commented on TBPH shares. ValuEngine cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 22nd. BidaskClub raised shares of Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Cantor Fitzgerald started coverage on shares of Theravance Biopharma in a research report on Monday, January 28th. They issued a “buy” rating and a $55.00 target price on the stock. Finally, Zacks Investment Research cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Theravance Biopharma presently has an average rating of “Hold” and a consensus target price of $43.40.
Several institutional investors and hedge funds have recently modified their holdings of TBPH. Norges Bank acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth about $22,422,000. Candriam Luxembourg S.C.A. acquired a new stake in shares of Theravance Biopharma during the third quarter worth about $8,321,000. Vanguard Group Inc lifted its position in shares of Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after purchasing an additional 126,135 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Theravance Biopharma by 3.6% during the third quarter. Vanguard Group Inc. now owns 3,672,030 shares of the biopharmaceutical company’s stock worth $119,965,000 after buying an additional 126,135 shares during the period. Finally, First Trust Advisors LP purchased a new stake in shares of Theravance Biopharma during the fourth quarter worth approximately $2,243,000. 84.42% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ TBPH opened at $22.95 on Tuesday. Theravance Biopharma has a 12 month low of $21.04 and a 12 month high of $35.48. The company has a debt-to-equity ratio of 6.52, a quick ratio of 5.41 and a current ratio of 5.41. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -5.75 and a beta of 1.69.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to staphylococcus aureus and other gram-positive bacteria.
Featured Story: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.